Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2015-04-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2015年第一季度报告全文
Regulatory Filings
2015-04-22 Chinese
重大资产购买报告书摘要（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "重大资产购买报告书" (Major Asset Purchase Report) from Guangdong Taicheng Pharmaceutical Co., Ltd. It discusses a significant asset acquisition involving the purchase of 100% equity of Haili Pharmaceutical. The document includes extensive information on the transaction background, pricing, funding sources, risk factors, approvals, and impact on the company. It contains financial data, legal opinions, independent financial advisor reports, and detailed descriptions of the transaction structure and implications. The length is substantial (15,000 characters), and it is not merely an announcement or a brief summary. The content aligns with a comprehensive report on a major asset purchase, which is a form of a significant corporate transaction. According to the filing definitions, this fits best under "Capital/Financing Update (CAP)" as it provides updates on company fundraising, financing activities, or capital structure changes related to the acquisition. It is not an Annual Report, Audit Report, or Merger & Acquisition filing (MA) since it focuses on asset purchase details rather than merger communications or proxy statements. It is also not a Regulatory Filing or Report Publication Announcement because it contains substantive financial and transaction details, not just a notice or certification. Therefore, the appropriate classification is CAP with high confidence.
2015-04-20 Chinese
关于重大资产重组复牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the resumption of trading of its stock following a suspension due to a major asset restructuring. It references prior announcements about the suspension and progress updates, mentions the approval of related proposals by the board, and notes regulatory review and inquiries. The document is short (1045 characters) and primarily serves to inform investors about the resumption of trading and ongoing corporate actions related to a major asset reorganization. It does not contain detailed financial statements or comprehensive report content but is an announcement about a capital restructuring event and stock trading status. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2015-04-20 Chinese
国信证券股份有限公司关于公司重大资产购买之独立财务顾问报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report (Revised)" for a major asset purchase by Guangdong Taicheng Pharmaceutical Co., Ltd. It is prepared by Guosen Securities Co., Ltd. as the independent financial advisor. The content includes detailed sections such as transaction overview, parties involved, transaction assets, contract terms, financial advisor's verification opinions, risk factors, and impact on the listed company. It references compliance with Chinese securities laws and regulations related to major asset restructuring and includes financial data, valuation, and risk disclosures. The document is comprehensive and substantive, clearly serving as an independent financial advisor report related to a major asset acquisition transaction. This type of document is distinct from a general annual report or earnings release and is specifically related to a major asset purchase transaction. According to the filing definitions, this fits best under "Capital/Financing Update (CAP)" as it provides detailed updates on a significant financing and capital transaction (major asset purchase). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or summary. Therefore, the classification is CAP with high confidence.
2015-04-20 Chinese
关于重大资产购买报告书的修订说明公告
Capital/Financing Update Classification · 95% confidence The document is titled as an announcement regarding revisions to a "重大资产购买报告书" which translates to "Major Asset Purchase Report". It discusses supplementary disclosures and clarifications related to a major asset purchase transaction, including risk factors, certifications, and operational impacts related to the acquisition. The document references a previously published major asset purchase report and provides updates and additional information in response to regulatory inquiries. This type of document is typical of a Capital/Financing Update (CAP) as it relates to significant corporate transactions involving asset purchases and related disclosures. It is not a full annual or interim report, audit report, or earnings release. It is also not a simple announcement of a report publication but contains substantive content about the transaction and its risks. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-04-20 Chinese
重大资产购买报告书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "广东台城制药股份有限公司 重大资产购买报告书（修订稿）" which translates to "Guangdong Taicheng Pharmaceutical Co., Ltd. Major Asset Purchase Report (Revised)". It details a major asset acquisition transaction, including transaction parties, transaction structure, pricing, funding sources, risk factors, management discussion and analysis, financial information of the target company, legal and financial advisor opinions, and compliance with regulatory requirements. The document is comprehensive and lengthy (15,000 characters), containing detailed financial and operational data related to the acquisition of 100% equity of Hainan Haili Pharmaceutical Co., Ltd. by Guangdong Taicheng Pharmaceutical. It is not a simple announcement or a brief summary but a full report on a significant asset purchase. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising, financing activities, or capital structure changes, specifically a major asset acquisition. It is not an Annual Report, Audit Report, or Merger & Acquisition filing per se, but a detailed report on a major asset purchase transaction, which aligns best with CAP.
2015-04-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.